Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hypertension Labeling Should Say Classes Are All Effective, But Unequally So

Executive Summary

Antihypertensive drug class labeling for cardiovascular outcomes should specify that some classes of agents are more effective at reducing such events than others, members of FDA's Cardiovascular & Renal Drugs Advisory Committee said

You may also be interested in...



Comparative Research Needs New Approach To Answer Real-Life Questions

To get the most out of the new funding for research on the comparative effectiveness of health care products and services, research needs to go in new directions so that it can answer real-world questions, two former CMS officials said at a recent forum at the American Enterprise Institute

Comparative Research Needs New Approach To Answer Real-Life Questions

To get the most out of the new funding for research on the comparative effectiveness of health care products and services, research needs to go in new directions so that it can answer real-world questions, two former CMS officials said at a recent forum at the American Enterprise Institute

Hypertension Class Labeling Does Not Release Sponsors From Large Trials

FDA should ensure that manufacturers do not construe the addition of outcomes claims to antihypertensive drug labels as lowering the approval standards for future hypertension agents, members of FDA's Cardiovascular & Renal Drugs Advisory Committee emphasized during an April 26 meeting

Related Content

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel